1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • August 2017
  • 128 pages
  • ID: 5064710

Summary

Table of Contents

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game!

In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan. It also details Japanese “Chuikyo” (Central and Social Regulatory Council) stand for Biosimilar penetration and regulatory approval requirement for non- JP specific dosage strength or/has clinical data from Ex-Japan clinical trial.

The report provide all the Japanese/Global players’ activities in biosimilar space for Japan market along with their pipeline deal history, current Mab tech platforms, alliances and deal structure. It details crisp summary on strategies of each key player (~36 JP local companies, multinational companies), their interest & focus for future collaboration in biosimilar space.

In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals- ~4000) and early entry of the player are critical factors to decide biosimilar penetration and market share dynamics of Japan Biosimilar Market.

While ongoing discussion of local originators to launch authorized generic BS in a way indicate cost pressure & threat on the originators by payers(Chuikyo), but put pause on attractiveness of developing BS for a mid size & generic pharma players. Small molecule authorized generics launch in Japan (Blopress- Aska, Plavix-Nichi Iko.) in last few years took major market share amongst generic players (>50%).

On the contrary, Biologics contribute significant part of the current healthcare spend (17% of total healthcare spend) by government in Japan. As the growth rate of drug cost are higher than the growth rate of the overall health care costs in Japan, and biologics are one of the major contributor to that- to reduce healthcare burden, a biosimilar weapon is a must need in Japan.

As per the recent survey of RA market in Japan amongst patient and Prescribers, ~40% of the patients/prescribers not used biologics to treat RA as it is expensive. To address these challenges and to make biosimilar development/use friendly environment, initiative to form JBSA (Japan biosimilar Association) has been in place in 2016. Separately, Government recent “Honebuto” Policy aims to double Biosimilar API by 2020 from Current (5 to 10), again confirms JP Government stands to aggressively push biosimilars use in Japan.

JBSA has done on the ground survey to handle Biosimilar penetration challenges and we expect this to result in government definite direction for efficient biosimilar development in Japan around 2018 with institutional reforms.

This may include remunerating prescribers/pharmacy/hospitals to use biosimilar, removing high cost medical care benefit system for increasing biosimilar penetration in Japan. High cost medical care benefit programme and various Government public Insurance programmes minimize the benefits of “co-pay difference” associated with biosimilar use. We expect evident change in these programmes in next NHI price revision to push prescribers/DPC hospitals to increase use for biosimilar in Japan.

Globally, a definite positive directions from USFDA to approve Biosimilars in US, recent success of Immuno Oncology Mabs on Innovation front and a steep uptake of these drugs in the Japan market, increased confidence of Japanese giants for more biopharma success in the coming time vs. small molecule to get breakthrough to grow.

These has allowed Japanese conglomerates to venture in global biologics CMO space in recent times (Asahi-Kasei – CMC biologics) and more M & A is expected in this direction to fulfill the gap of Biopharma-MAb technology platforms amongst Japanese Players.

Based on the FY2016 sales reported by major biopharma drugs in Japan- Biosimilars are an opportunity of cumulative market size of ¥630b (Table 3) in next few years for Japan biosimilar players.

In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan. It also details Japanese “Chuikyo” (Central and Social Regulatory Council) stand for Biosimilar penetration and regulatory approval requirement for non- JP specific dosage strength or/has clinical data from Ex-Japan clinical trial.

The report provide all the Japanese/Global players’ activities in biosimilar space for Japan market along with their pipeline deal history, current Mab tech platforms, alliances and deal structure. It details crisp summary on strategies of each key player (~36 JP local companies, multinational companies), their interest & focus for future collaboration in biosimilar space.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Oncology Biosimilars Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

Oncology Biosimilars Industry: Forecasts to 2025

  • $ 5795
  • Industry report
  • September 2017
  • by Transparency Market Research

Global Oncology Biosimilars Market: OverviewThis report on the oncology biosimilars market analyzes the current and future scenario of the global market. Increasing prevalence of cancer, innovation in ...

Clinical Trial Strategies in Biosimilar Drug Development

Clinical Trial Strategies in Biosimilar Drug Development

  • $ 10000
  • Industry report
  • October 2017
  • by Datamonitor Healthcare

As the patent cliff for many blockbuster biologic therapies is approaching, clinical development programs for biosimilar options to those therapies are emerging at a rapid pace. Among the key areas of ...

PHARMA LEADER SERIES: 25 TOP BIOSIMILAR DRUG MANUFACTURERS 2017-2027

PHARMA LEADER SERIES: 25 TOP BIOSIMILAR DRUG MANUFACTURERS 2017-2027

  • $ 3247
  • Industry report
  • August 2017
  • by Visiongain

And Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor BiologicsReport DetailsWho Are the Leaders in the Emerging Biosimilar Drugs Market? Visiongain’s New Analysis ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.